Extension study for AVTX-803 in LAD type II
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial is a follow-up study testing whether AVTX-803 continues to be safe and effective for people with Leukocyte Adhesion Deficiency type II (LAD II). If you already took part in an earlier AVTX-803 LAD II study, this may be the next step while researchers monitor benefits and side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You finished the earlier AVTX-803 LAD-301 study
- Your LAD II diagnosis has been confirmed by blood tests and genetic testing
- Your hemoglobin level is not severely low (must be 8.0 g/dL or higher)
- Your kidneys are working well enough (eGFR must be 90 mL/min or higher)
- You have not had a bad reaction or allergy to fucose or ingredients in the medicine
- You do not have a past history (in the investigator’s view) of not responding to fucose at adequate doses
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests whether AVTX-803 can help prevent or improve infections in people with Leukocyte Adhesion Deficiency (LAD) type II. The study also checks how safe the drug is.
This study tests a sugar called D-galactose given as a supplement to help with symptoms of SLC35A2-CDG, a rare genetic condition that can cause seizures and digestive problems. The goal is to see if taking this sugar improves those symptoms.
This is a follow-up (no new treatment) study for people who previously received a gene therapy made from their own cells for ADA-SCID. It mainly tracks long-term safety and whether a marker showing the gene change can still be found.
This study tests a new cell-based treatment called LV009 in people with certain blood cancers, autoimmune diseases, or antibodies that make transplants difficult. The treatment is meant to fight the disease or reduce harmful antibodies, possibly helping patients who have not responded to other therapies.
This study follows people who previously got the experimental drug NTLA-2002 in an Intellia trial. It checks long-term safety and health effects, even if you already stopped treatment.
This Phase 1/2 study tests AVM0703 in people ages 12+ with certain lymphoid cancers that have returned or not responded to treatment. It may help shrink the cancer or control it when other treatments have failed or are not possible.
Hear when a new Leukocyte Adhesion Deficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.